481412
NF-kB Activation Inhibitor IV
The NF-kB Activation Inhibitor IV, also referenced under CAS 139141-12-1, controls the biological activity of NF-kB. This small molecule/inhibitor is primarily used for Inflammation/Immunology applications.
别名:
NF-kB Activation Inhibitor IV, (E)-2-Fluoro-4ʹ-methoxystilbene
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H13FO
化学文摘社编号:
分子量:
228.26
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
产品名称
NF-kB Activation Inhibitor IV, The NF-kB Activation Inhibitor IV, also referenced under CAS 139141-12-1, controls the biological activity of NF-kB. This small molecule/inhibitor is primarily used for Inflammation/Immunology applications.
InChI key
ILVFNAZMSMNXJG-RMKNXTFCSA-N
SMILES string
Fc1c(cccc1)\C=C\c2ccc(cc2)OC
assay
≥98% (HPLC)
form
crystalline solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
solubility
DMSO: 20 mg/mL
shipped in
ambient
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Cell permeable: yes
Primary Target
NF-κB Activation
NF-κB Activation
Product does not compete with ATP.
Reversible: no
Target IC50: 150 nM inhibiting TNF-α-stimulated NF-κB reporter activity in 293T cells.
Disclaimer
Toxicity: Standard Handling (A)
General description
A cell-permeable trans-stilbene Resveratrol (Cat. No. 554325) analog that exhibits much enhanced anti-inflammatory potency, but no anti-oxidant activity. Suppresses LPS-induced COX-2 mRNA expression in BV-2 cells (~46% inhibition at 150 nM) and Shown to be ~130-fold more potent than Resveratrol in inhibiting TNF-α-stimulated NF-κB reporter activity in 293T cells (IC50 = 150 nM).
Other Notes
Heynekamp, J.J., et al. 2006. J. Med. Chem.49, 7182.
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Pascal Gelebart et al.
Translational oncology, 4(1), 9-19 (2011-02-03)
Mantle cell lymphoma (MCL) is a specific type of aggressive B-cell non-Hodgkin lymphoma. We recently found that IL-22RA1, one of the two subunits of the interleukin 22 (IL-22) receptor, is expressed in MCL cell lines but not benign lymphocytes. In
Je Sun Lim et al.
Cell death & disease, 13(11), 1002-1002 (2022-11-27)
Glioblastoma (GBM) is a highly vascular malignant brain tumor that overexpresses vascular endothelial growth factor (VEGF) and phosphofructokinase 1 platelet isoform (PFKP), which catalyzes a rate-limiting reaction in glycolysis. However, whether PFKP and VEGF are reciprocally regulated during GBM tumor
Yun-Ru Jaoying Huang et al.
Journal of cellular physiology, 237(12), 4517-4530 (2022-10-18)
Golgi apparatus (GA) and centrosome reposition toward cell leading end during directional cell migration in a coupling way, thereby determining cell polarity by transporting essential factors to the proximal plasma membrane. The study provides mechanistic insights into how GA repositioning
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持